Clinicopathologic features and KRAS mutation incidence of gastric carcinomas

Objectives: This study aims to determine the frequency of KRAS mutations in patients with gastric adenocarcinoma (GAC) in Hatay province, and to determine the relationship of this mutation with some pathological and clinical parameters and to guide the diagnosis and treatment planning of patients....

Full description

Bibliographic Details
Main Authors: Didar Gürsoy, İlke Evrim Seçinti, Esin Doğan, Muhyittin Temiz
Format: Article
Language:English
Published: Rabia Yılmaz 2022-01-01
Series:Journal of Contemporary Medicine
Subjects:
Online Access:https://dergipark.org.tr/tr/download/article-file/1912312
_version_ 1827980131007725568
author Didar Gürsoy
İlke Evrim Seçinti
Esin Doğan
Muhyittin Temiz
author_facet Didar Gürsoy
İlke Evrim Seçinti
Esin Doğan
Muhyittin Temiz
author_sort Didar Gürsoy
collection DOAJ
description Objectives: This study aims to determine the frequency of KRAS mutations in patients with gastric adenocarcinoma (GAC) in Hatay province, and to determine the relationship of this mutation with some pathological and clinical parameters and to guide the diagnosis and treatment planning of patients. Methods: Formalin-fixed, paraffin-embedded, and histologically confirmed samples were used in the assessment of KRAS mutation. Sections were taken from the archive tissue samples of each case. Real-Time Polymerase Chain Reaction (RT-PCR) system was used to identify mutations of codons 12 and 13 (exon 2) of the RAS gene. Mutations of GLY12ALA (G12A), GLY12ASP (G12D), GLY12ARG (G12R), GLY12CYS (G12C), GLY12SER (G12S), GLY12VAL (G12V), GLY13ASP (G13D) were performed. Results: The mutation rate of KRAS was 2% and only one substitution, G12D, was detected. In this case, the tumor was located in the small curvature. Since the number of cases with mutations was low, statistical comparison could not be made between KRAS mutation and clinicopathological factors. A significant difference was found between tumor differentiation and WHO-2010 typing and primary tumor stage. Conclusions: We found the incidence of KRAS mutation to be 2%. We also estimate that the G12D mutation may be associated with GAC site and surgical margin. Although KRAS mutation in GAC alone is not a prognostic or predictive marker, subtype-specific analysis may provide data that may affect the diagnosis, management and treatment of the disease
first_indexed 2024-04-09T21:48:50Z
format Article
id doaj.art-72f7aa8a474b453c9452d2c21c6dbca4
institution Directory Open Access Journal
issn 2667-7180
language English
last_indexed 2024-04-09T21:48:50Z
publishDate 2022-01-01
publisher Rabia Yılmaz
record_format Article
series Journal of Contemporary Medicine
spelling doaj.art-72f7aa8a474b453c9452d2c21c6dbca42023-03-24T19:43:26ZengRabia YılmazJournal of Contemporary Medicine2667-71802022-01-011211510.16899/jcm.9796651809Clinicopathologic features and KRAS mutation incidence of gastric carcinomasDidar Gürsoy0İlke Evrim Seçinti1Esin Doğan2Muhyittin Temiz3HATAY MUSTAFA KEMAL ÜNİVERSİTESİ, TAYFUR ATA SÖKMEN TIP FAKÜLTESİ, CERRAHİ TIP BİLİMLERİ BÖLÜMÜ, PATOLOJİ ANABİLİM DALIHATAY MUSTAFA KEMAL ÜNİVERSİTESİ, TAYFUR ATA SÖKMEN TIP FAKÜLTESİ, CERRAHİ TIP BİLİMLERİ BÖLÜMÜ, PATOLOJİ ANABİLİM DALIHATAY MUSTAFA KEMAL ÜNİVERSİTESİ, TAYFUR ATA SÖKMEN TIP FAKÜLTESİ, CERRAHİ TIP BİLİMLERİ BÖLÜMÜ, PATOLOJİ ANABİLİM DALIHATAY MUSTAFA KEMAL ÜNİVERSİTESİ, TAYFUR ATA SÖKMEN TIP FAKÜLTESİ, CERRAHİ TIP BİLİMLERİ BÖLÜMÜ, GENEL CERRAHİ ANABİLİM DALIObjectives: This study aims to determine the frequency of KRAS mutations in patients with gastric adenocarcinoma (GAC) in Hatay province, and to determine the relationship of this mutation with some pathological and clinical parameters and to guide the diagnosis and treatment planning of patients. Methods: Formalin-fixed, paraffin-embedded, and histologically confirmed samples were used in the assessment of KRAS mutation. Sections were taken from the archive tissue samples of each case. Real-Time Polymerase Chain Reaction (RT-PCR) system was used to identify mutations of codons 12 and 13 (exon 2) of the RAS gene. Mutations of GLY12ALA (G12A), GLY12ASP (G12D), GLY12ARG (G12R), GLY12CYS (G12C), GLY12SER (G12S), GLY12VAL (G12V), GLY13ASP (G13D) were performed. Results: The mutation rate of KRAS was 2% and only one substitution, G12D, was detected. In this case, the tumor was located in the small curvature. Since the number of cases with mutations was low, statistical comparison could not be made between KRAS mutation and clinicopathological factors. A significant difference was found between tumor differentiation and WHO-2010 typing and primary tumor stage. Conclusions: We found the incidence of KRAS mutation to be 2%. We also estimate that the G12D mutation may be associated with GAC site and surgical margin. Although KRAS mutation in GAC alone is not a prognostic or predictive marker, subtype-specific analysis may provide data that may affect the diagnosis, management and treatment of the diseasehttps://dergipark.org.tr/tr/download/article-file/1912312krasmide kanserig12dmutasyonkrasgastric carcinomag12dmutation
spellingShingle Didar Gürsoy
İlke Evrim Seçinti
Esin Doğan
Muhyittin Temiz
Clinicopathologic features and KRAS mutation incidence of gastric carcinomas
Journal of Contemporary Medicine
kras
mide kanseri
g12d
mutasyon
kras
gastric carcinoma
g12d
mutation
title Clinicopathologic features and KRAS mutation incidence of gastric carcinomas
title_full Clinicopathologic features and KRAS mutation incidence of gastric carcinomas
title_fullStr Clinicopathologic features and KRAS mutation incidence of gastric carcinomas
title_full_unstemmed Clinicopathologic features and KRAS mutation incidence of gastric carcinomas
title_short Clinicopathologic features and KRAS mutation incidence of gastric carcinomas
title_sort clinicopathologic features and kras mutation incidence of gastric carcinomas
topic kras
mide kanseri
g12d
mutasyon
kras
gastric carcinoma
g12d
mutation
url https://dergipark.org.tr/tr/download/article-file/1912312
work_keys_str_mv AT didargursoy clinicopathologicfeaturesandkrasmutationincidenceofgastriccarcinomas
AT ilkeevrimsecinti clinicopathologicfeaturesandkrasmutationincidenceofgastriccarcinomas
AT esindogan clinicopathologicfeaturesandkrasmutationincidenceofgastriccarcinomas
AT muhyittintemiz clinicopathologicfeaturesandkrasmutationincidenceofgastriccarcinomas